Janux Therapeutics (JANX) EBIT (2020 - 2026)

Janux Therapeutics (JANX) has reported EBIT for 7 consecutive years, with -$34.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBIT rose 1.96% year-over-year to -$34.2 million; the TTM figure through Mar 2026 stood at -$157.0 million (down 38.21% YoY), while the FY2025 annual figure was -$157.7 million, down 59.51% from the prior year.
• EBIT improved to -$34.2 million in Q1 2026 per JANX's latest filing, from -$42.4 million in the prior quarter.
• Across five years, EBIT topped out at -$13.5 million in Q1 2022 and bottomed at -$45.1 million in Q2 2025.
• Historically, EBIT has averaged -$25.3 million across 5 years, with a median of -$20.3 million in 2023.
• Annual changes were most pronounced in 2022 — EBIT tumbled 492.91% — and 2024, when it jumped 33.38%.
• Janux Therapeutics' EBIT stood at -$18.3 million in 2022, then gained by 11.66% to -$16.1 million in 2023, then slumped by 79.85% to -$29.0 million in 2024, then sank by 46.1% to -$42.4 million in 2025, then increased by 19.31% to -$34.2 million in 2026.
• Business Quant data shows JANX's EBIT at -$34.2 million in Q1 2026, -$42.4 million in Q4 2025, and -$35.3 million in Q3 2025.